Galectin Therapeutics to Present at the Singular Research Summer Conference

NORCROSS, Ga., July 07, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. GALT, the leading developer of therapeutics that target galectin proteins, today announced that Harold Shlevin, Ph.D., the Company's chief operating officer, will be presenting on behalf of the Company at the Singular Research Summer Solstice Conference being held on Thursday, July 13, 2017 at the Metro Meeting Centers in Boston, MA. Dr. Shlevin's presentation is scheduled to begin at 3:30 p.m. ET.

A live webcast of the presentation may be accessed on the Investor Relations section of the Galectin Therapeutics website at www.galectintherapeutics.com. A replay of the webcast will be available after the event.

In addition to his presentation, Dr. Shlevin will take part in a series of 1x1 and small group meetings.

Singular Research is a trusted supplier of independent, single-source research on small-to-micro cap companies to small-to-medium sized Hedge Fund managers. Singular Research provides quarterly updates for over 40 companies.

About Galectin Therapeutics
Galectin Therapeutics is developing promising therapies for the treatment of fibrotic liver disease, skin diseases, and cancer based on the Company's unique understanding of galectin proteins, which are key mediators of biologic function. Galectin seeks to leverage extensive scientific and development expertise as well as established relationships with external sources to achieve cost-effective and efficient development. The Company is pursuing a development pathway to clinical enhancement and commercialization for its lead compounds in liver fibrosis and cancer. Additional information is available at www.galectintherapeutics.com.

Contacts:
Jack Callicutt, Chief Financial Officer
(678) 620-3186
ir@galectintherapeutics.com.